FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

3 ,

OMB APPROVAL									
OMP Number:	2225.02								

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* KAPLAN LESTER J PH D (Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC. 3911 SORRENTO VALLEY BOULEVARD					2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD] 3. Date of Earliest Transaction (Month/Day/Year) 06/12/2009							(Ch	Relationship of Reporting Pe Check all applicable) X Director Officer (give title below)			10% Ow Other (s below)	vner	
(Street) SAN DIEGO CA 92121				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5)		(Zip)															
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) Table II - Derivati					action Day/Year	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transacti Code (Ins 8) Code V	ion 5 str. 5	1. Securit Disposed 5) Amount	(A) or	Price	5. Amour Securitie Beneficia Owned Reported Transact (Instr. 3 a	Amount of ecurities eneficially (D) wheel Following eported ransaction(s) nstr. 3 and 4)		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, Ti	ransacti	ion	5. Number of		6. Oate Exercisable Expiration Date (Month/Day/Year)			vertible securiti and 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	e (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				С	ode V	,	(A)	(D)	Date Exercisable		oiration e	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$2.16	06/12/2009			A		10,000		(1)	06/1	11/2019	Common Stock	10,000	\$0	10,000	0	D	
Stock Option (right to buy)	\$2.16	06/12/2009			A		34,722		(1)	06/1	11/2019	Common Stock	34,722	(2)	34,72	2	D	

Explanation of Responses:

- 1. 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.
- 2. The Reporting Person has elected to convert annual retainer fees of \$25,000 into a stock option under the terms of the Issuer's Outside Director Compensation Program.

/s/ Uli Hacksell, attorney-infact 06/16/2009

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.